PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars

Transcription

1 PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update

2 Growth in PBS spending was negative in , including rebates 16.2% 9.2% 9.1% 9.4% 9.2% 9.0% 5.2% 6.1% 4.3% 3.2% 1.9% -4.5% -3.5% Source: PBS Statistics, Department of Health (including revenue)

3 PBS Growth The changing composition of the PBS PBS Top 10 in transition Shifting sands for industry as generic volume soars The under co-payment market

4 PBS spending is shifting to highly specialised drugs Growth by category to $596 $574 $351 $156 -$11 -$259 Concessional General HSD S100 Revenue Total $5,383m $1,505m $1,209m $946m $574m $8,498m* $5,642m $1,516m $858m $350m $49m $8,342m* Source: PBS Statistics, Department of Health (*includes Drs Bag and Safety Net Cards)

5 PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market

6 PBS Top 10 drugs by cost to Government share of total PBS spending The Top 10 is not what it used to be 25% 19% Source: Department of Health (excluding rebates)

7 In , the Government spent almost $830 million less on the PBS Top 10 Drug Brand Treats Govt Cost in Govt Cost in Atorvastatin LIPITOR Cholesterol $593m $123m 10 Rosuvastatin CRESTOR Cholesterol $359m $215m 2 Ranibizumab LUCENTIS Macular degeneration Adalimumab HUMIRA Rheumatoid arthritis Fluticasone with Salmeterol $307m $157m 7 $198m $312m 1 SERETIDE Asthma $169m $177m 3 Esomeprazole NEXIUM Reflux $168m $174m 5 Olanzapine ZYPREXA Depression $159m $65m 24 Clopidogrel* PLAVIX Blood thinner $133m Etanercept ENBREL Rheumatoid arthritis, etc $127m $163m 6 Tiotropium SPIRIVA COPD $117m $116m 11 TOTALS $2,330m $1,502m Source: PBS Statistics, Department of Health (Section 85 only) * No longer in the top Rank by Govt Cost

8 The total cost to Government of the drugs that make up the PBS Top 10 has fallen by almost $250 million in three years largely due to cholesterol lowering medicines Drug Brands Treats Govt Cost in Adalimumab HUMIRA Rheumatoid arthritis Govt Cost in $198m $312m 4 Rosuvastatin CRESTOR* Cholesterol $359m $215m 2 Fluticasone with Salmeterol SERETIDE Asthma/COPD $169m $177m 5 Aflibercept EYLEA Macular degeneration $174m n/a Esomeprazole NEXIUM* Reflux $168m $174m 6 Etanercept ENBREL Rheumatoid arthritis Ranibizumab LUCENTIS Macular degeneration $127m $163m 9 $307m $157m 3 Insulin Glargine LANTUS Diabetes $105m $145m 8 Fingolimod GILENYA MS $138m n/a Atorvastatin LIPITOR* Cholesterol $593m $123m 1 TOTALS $2,026m $1,778m Source: PBS Statistics, Department of Health (Section 85 only) * Off-patent originator brand Ranking by Govt Cost

9 PBS spending has shifted towards biologics Change in Government cost to Insulin Glargine $50m Ranibizumab Aflibercept Etanercept -$150m $174m $36m Total Govt cost of Top 10 biologics has grown by $224m Adalimumab $114m Fingolomod $138m Fluticasone with Salmeterol Esomeprazole Atorvastatin -$470m $11m $6m Total Govt cost of Top 10 small molecules has fallen by $459m Rosuvastatin -$144m Source: PBS Statistics, Department of Health (Section 85 only)

10 PBS Growth The changing composition of the PBS PBS Top 10 drugs in transformation Shifting sands for industry The under co-payment market

11 Significant change in company sales performance in the past three years Company PBS Ex-Man sales Company PBS Ex-Man sales Pfizer $1,140m Pfizer $602m AstraZeneca $862m Novartis $553m Sanofi $447m MSD $348m GSK $293m Alphapharm $272m Abbott/AbbVie $271m Janssen $259m Lilly $249m Apotex $190m Boehringer Ingelheim $184m Aspen $167m Roche $140m NovoNordisk $116m AstraZeneca $509m Novartis $560m AbbVie $359m MSD $337m Sanofi $327m Bayer $309m Janssen $308m GSK $301m Apotex $279m Alphapharm $255m Boehringer Ingelheim $197m NovoNordisk $140m BMS $139m Mundipharma $139m BMS $107m Source: PBS Statistics, Department of Health derived ex-manufacturer sales (Section 85 only)

12 Generic companies dominated prescription volume in Market share by PBS prescription - Alphapharm Apotex 13.0% Aspen 9.1% Pfizer 7.3% AstraZeneca 7.2% Sanofi 5.5% Sandoz 5.1% GSK 4.6% MSD 4.1% BI 3.1% Servier 2.5% Fawns and McAllan 2.1% Mundipharma 1.9% Ascent 1.8% Novartis 1.6% Janssen 1.3% Alcon 1.1% Bayer 1.1% Abbott 1.0% Ranbaxy 1.0% Source: PBS Statistics, Department of Health Prescription volume market share (Section 85 only) to %

13 PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market

14 A steady increase in the number of PBS prescriptions dispensed under co-payment 72,322,451 79,031,195 62,019, Source: PBS Statistics, Department of Health

15 Cardiovascular scripts continue to move below co-pay as price disclosure hits 11,762,386 12,031, ,790, ,362,258 Atorvastatin RAS-acting agents* Source: PBS Statistics, Department of Health * ARBS, ACE inhibitors and direct renin inhibitors